Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.40 0.54% 75.00 74.40 75.80 77.00 74.40 77.00 105,651 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 30.6 341

Ekf Diagnostics Share Discussion Threads

Showing 3726 to 3748 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
29/7/2021
16:18
9 months on and still under 80. Food for thought maybe? Huge opportunity cost concept comes to mind. Been a raging bull market everywhere else.
tongosti
29/7/2021
08:58
Further food for thought - Recently the US Centers for Disease Control and Prevention, announced that FDA emergency use authorization (EUA) for its 'own' COVID-19 PCR test will be withdrawn at the end of 2021. Some analysts are suggesting that this planned withdrawal could mark a bellwether of Emergency Use Authorisation (EUA) approved COVID-19 tests coming to an end. If this proves to be the case then this could have a large impact on the entire COVID-19 testing industry in the U.S., which is currently comprised almost entirely of COVID-19 tests with only FDA EUA approval, which is similarly applicable to sample collection devices (currently FDA submissions are experiencing longer-than-typical review timelines and delays in initiation of reviews). In contrast to fully FDA approved medical tests, EUAs are only given during a declared emergency; outside of this, an EUA cannot be given and cannot be used, with the same applying to viral transport media. With the pandemic situation at least improving in the US, and economies opening up, the fact that state of emergency cannot last forever is likely to be coming firmly to mind. If the above scenario comes to pass, or for that matter is already being anticipated, then the fact that PrimeStore MTM is a patented, fully FDA cleared sample collection system, should come to the fore in terms of availability post EUA's, not to mention its other enabling and important attributes. However, testing will remain paramount in the monitoring of the prevalence of COVID-19, and thus COVID-19 tests will still be needed, similar to how influenza testing is regularly used. Hence my previous comment implying that PrimeStore MTM is not a flash in the pan product, far from it! And due in part to the pandemic, PrimeStore MTM's has been put firmly onto the map, and its place in terms of diagnostics, sequencing (perhaps overlooked, but very important!) and indeed preparedness, has almost certainly been cemented as a permanent one. I would also add that this applies to many uses outside of Covid-19 detection. I am therefore expecting sample collection products (not just MTM) to become an integral part of EKF's core business, especially as this also dovetails with diagnostic kit production that brings testing closer to the consumer, which as recently indicated, is likely to become a multi-year, irreversible growth opportunity.
wan
28/7/2021
10:39
Food for thought...With Covid now being considered as being with us forever, it's worth keeping mind that as the "influenza season" draws nearer, that PrimeStore MTM can be used to detect and differentiate SARS-CoV-2 from influenza viruses. So, in this regard, I am expecting PrimeStore MTM to potentially be in routine use forever too! PrimeStore MTM has proven effective for high throughput and point of care SARS-CoV-2, Influenza, and multiplex testing (single test to diagnose infection caused by more than one virus). And most recently PrimeStore MTM was validated for the rapid and safe simultaneous detection of SARS-CoV-2 (COVID-19) and influenza A/B viruses on Roche’s cobas Liat®, a point-of-care FDA approved diagnostic system. In short, a sample transport medium that's compatible and safe in differentiating between covid and flu, either separately from the same sample on a range of high-throughput systems, via the same sample for multiplex testing, or simultaneously on point of care platforms.
wan
27/7/2021
07:08
Exceprt from SourceBio's Half Year Trading Update today - As previously reported, the Company anticipates a strong second half bias to revenues, earnings and cash generation, largely driven by the phasing of COVID-19 testing revenues generated through its newest business unit, Infectious Disease Testing. The Group had a solid first half and has completed more than 600,000 PCR-based tests from its laboratory in Nottingham during the period, in addition to tests delivered through mobile units, generating divisional revenues in the half year of approximately GBP28.4 million compared to GBP2.2 million in the first half of 2020. The Group is planning for a significant uplift in demand in the third quarter driven by the anticipated increase in COVID-19 testing as travel restrictions continue to be lifted. The Group has already seen a marked uptick during July with daily testing volumes rising from under 4,000 tests per day in June to approximately 9,000 tests daily at present, well within the Group's existing capacity. Testing demand is expected to rise further and, accordingly, the Group has made preparations to expand its capacity to more than 20,000 tests per day. Should demand exceed these levels, the Group has further arrangements to leverage surplus capacity within a third party owned laboratory. hTTps://uk.advfn.com/stock-market/london/sourcebio-SBI/share-news/SourceBio-International-PLC-Half-Year-Trading-Upda/85671726
wan
24/7/2021
11:28
As predicted, PCR testing volumes has almost certainly increased and perhaps significantly, and (unfortunately) it appears it could stay at relatively high levels going forwards - UK lacks testing capacity to bring pingdemic to a swift end, ministers warned System will not easily be able to meet demand if relaxation of self-isolation rules brought forward, sources say By Ben Riley-Smith, POLITICAL EDITOR; Bill Gardner and Lizzie Roberts 23 July 2021 Even though the daily Covid case count has dipped in recent days, there are concerns in Whitehall that the dropping of almost all major restrictions earlier this week could trigger a new surge. The limits of testing – both PCR and lateral flow tests – are closely linked to the debate about when self-isolation rules can change. One source said that last week ministers ordered more lateral flow tests amid fears they would "run out" by around mid-August. The availability of PCR tests is also coming under pressure. Last week, the NHS admitted that turnaround times for testing in the community had "decreased substantially" since May. Official figures show that the percentage of tests processed within 24 hours fell sharply from 93 per cent in May to 64 per cent in the week ending July 14. A testing source said turnaround times could fall even further if the change to self-isolation rules was brought forward. They warned this could push processing times beyond 72 hours, when samples can go off and produce false negatives. "We are therefore calling on you to ensure that the necessary testing is in place to enable people who have been double vaccinated for longer than two weeks and pinged by the NHS Covid app, to immediately return to work, following a negative PCR test, rather than having to self-isolate.” A Department of Health and Social Care spokesman said: "The testing and tracing being delivered across the country is saving lives every single day and stopping the spread of the virus by breaking chains of transmission and helping to control outbreaks wherever they exist. "NHS Test and Trace has capacity in place to respond to increases in demand and people can have confidence that if they need a test, they can get one. Anyone who has Covid-19 symptoms can book home-testing PCR kits and more booking slots are made available at testing sites each day." Full story - hTTps://www.telegraph.co.uk/news/2021/07/23/uk-lacks-testing-capacity-bring-pingdemic-swift-end-ministers/ And with regard to a particular point raised in the above article that "this could push processing times beyond 72 hours, when samples can go off and produce false negatives." EKF has an answer to that! Cue the attributes of PrimeStore MTM (even if its just in case any extension of the processing times waste the sample and extend the whole testing process further and exacerbating the situation!). It's also why Primestore MTM is effective in enabling downstream sequencing, despite any such delays. Note that EKF has already confirmed that supply contracts have be won with Public Health England, Private Labs and Universities in the UK and has a large contract with distributor to supply the Government of Ireland.
wan
24/7/2021
11:03
In my view, the broad-based strength this large player experienced in the first half provides a good guide/overview of the sector, with the full year outlook also providing a reassuring feature, and at the very least, complimenting the confidence announced by EKF's management in terms of the full year, and indeed the impact from the delivery of their growth strategy - Sciences and Diagnostics Businesses Jul 22, 2021 This story has been updated with information from Danaher's analyst conference call. NEW YORK – Danaher reported before the opening of the market on Thursday that its second quarter revenues rose 37 percent year over year, thanks largely to steep gains from its life sciences and diagnostics businesses. For the three months ended July 2, revenues rose to $7.22 billion from $5.30 billion in the second quarter of 2020, beating the average Wall Street analyst estimate for revenues of $6.72 billion. Revenues for the life sciences business rose 41 percent to $3.73 billion from $2.64 billion, revenues for the diagnostics business also rose 41 percent to $2.34 billion from $1.66 billion, and the company saw a 16 percent increase in the environmental and applied solutions business to $1.15 billion in revenue from $995.0 million in the year-ago quarter. "Broad-based strength across the portfolio helped us deliver over 30 percent core revenue growth and outstanding earnings per share growth and cash flow generation," Danaher President and CEO Rainer Blair said in a statement. "We continued to make significant growth investments during the quarter, strengthening our organic growth trajectory and enhancing our portfolio with the announcement of our pending acquisition of Aldevron." Danaher ended the quarter with $7.32 billion in cash and cash equivalents. For the third quarter, the company said it expects core revenue growth in the mid- to high-teens percent range. Blair said the company expects to deliver approximately 20 percent core revenue growth for full-year 2021. Danaher also expects to recognize $2 billion in COVID-related vaccine and therapeutic revenues in 2021 and anticipates entering 2022 with approximately $1.5 billion in COVID-related backlog revenue. He also noted the company expects to ship approximately 50 million respiratory tests in 2021. Full story - hTTps://www.360dx.com/business-news/danaher-q2-revenues-rise-37-percent-driven-life-sciences-and-diagnostics-businesses#.YPvVHo5KiF4
wan
23/7/2021
16:02
wrong thread
pugugly
23/7/2021
07:41
News coverage for the above report - Report calls for breakthrough diagnostics to be funded like new medicines 21 JULY 2021 The Future of Diagnostics Delivery in the UK report, which is backed by both the Institute of Biomedical Science (IBMS) and the Association of British HealthTech Industries (ABHI), is based on interviews with leading figures in Government, the NHS and UK pathology community. The findings highlight the clear discrepancy between the value diagnostics deliver to the health system and the investment it currently receives, and focuses on three key areas of development for strengthening the UK diagnostics sector of the future and improving patient access to diagnostic innovations: Expanding the size and profile of the NHS pathology service; Developing the future testing landscape; and Increasing the uptake of innovative diagnostics across care pathways. hTTps://www.med-technews.com/news/Medtech-Diagnostics-news/report-calls-for-breakthrough-diagnostics-to-be-funded-like-/
wan
23/7/2021
07:38
The pandemic has brought diagnostics into sharper focus. The following report and its recommendations are insightful and provides for a very worthwhile read - The Future of Diagnostics Delivery in the UK Roche Diagnostics Limited July 2021 The COVID-19 pandemic has demonstrated beyond any reasonable doubt the essential role that diagnostics play in the health of every citizen in this country. From prevention to disease management, diagnostic testing has always been vital to patient outcomes, with in vitro diagnostics informing 70% of all clinical decisions taken in the NHS. When we consider, however, that for every £100 spent in the NHS, only £1 will be invested in diagnostic testing, there is a clear discrepancy between the value the UK places on diagnostics, and our investment in them. This country is a global leader in clinical discovery and scientific excellence, and the NHS is world renowned for its workforce, safety and efficiency. Yet, the fact remains that for many major diseases, we fall behind other leading economies in terms of our outcomes. The historic lack of investment in diagnostics is, tragically, a key factor in this disparity, and one with far reaching consequences. When the pandemic hit in early 2020, we simply did not have the same diagnostic tools, assured supplies and infrastructure as other European countries to rapidly test for a novel virus. Since the start of the COVID-19 pandemic, so much has changed. We have seen unprecedented collaboration between the NHS, Government, the pathology sector and the diagnostics industry in the UK. New partnerships and ways of working have been forged to establish the rapid and effective testing infrastructure necessary to meet the scale and severity of the challenge we face. The focus on diagnostics may have historically come second to treatment, cures or vaccines, but the importance of testing in this global pandemic has proved beyond doubt its role as the cornerstone of every treatment pathway. This must now be the catalyst for a bigger conversation on how we address the wider impact of COVID-19 on health outcomes in the UK. Conclusion The essential role diagnostic innovations play in delivering improved outcomes, driving efficiencies and curbing outbreaks has long been recognised by the health system. However, they have never been embraced at the scale or speed needed to realise their true potential. 2020/21 has changed the approach of the NHS towards diagnostics for good. At a time when the world around us continues to change faster than ever before, we must not simply keep pace with this change, but show the world what can be done. As we look towards the next 12 months, Roche Diagnostics stands ready to continue to partner with Government, the NHS and the pathology professional bodies to realise the recommendations in this document and help create a diagnostics industry in the UK fit for the future. hTTps://dianews.roche.com/rs/106-RRW-330/images/The%20Future%20of%20Diagnostics%20Delivery%20in%20the%20UK%20report.pdf
wan
22/7/2021
17:31
No specific insight yet that I can recall, aside from indicating a target of one investment per year and one floatation per year. And according to the Growth Strategy, EKF continue to be in conversations with MSIP over future initiatives and they will look to update investors at the Interim Statement in September 2021 (page 13) - hTTps://www.ekfdiagnostics.com/res/EKF%20Investor%20Presentation%20June%202021%20Growth%20strategy%202021-2024.ppt.pdf
wan
22/7/2021
15:55
Yes they have.
tongosti
21/7/2021
16:04
Have shareholders been given any insight into future opportunities which may flow from the relationship with Mt Sinai?
chrysalis99
21/7/2021
11:33
Is all the diagnostics revenue classified as non-core or just the Covid-19 testing? As rivaldo points out, the latter seems likely to be ongoing for several years, with EKF hopefully continuing to gain significant revenue from this. As well as being useful revenue and profits, it will increase the scope for earnings enhancing acquisitions.
shanklin
21/7/2021
11:16
LOL - tongosti is obviously someone who waits to buy at the top ! I first invested here at 50p last August so in just under a year the value of my original holding has increased by 49%. Having subsequently added some more, my average cost is now 55.2p and therefore my current gain is circa 35%. Hardly a price that has been in limbo over that period. My "investor euphoria" has so far paid off well in comparison to his "gloom from the sidelines" approach !
masurenguy
21/7/2021
11:16
Thanks Welshborderer. I have a strictly personal view with regard to the share price, suffice to say it potentially sits north of £1, whilst collecting dividends on the way as well as benefiting from the opportunities generated from the partnership with Mount Sinai. It's therefore reassuring to read the albeit limited note above from Singer regarding the potential, hence I am looking forward to the delivery of early phases of the growth plan. Plus, I note we now have clarity regarding the growth plan being funded from current cash resources.
wan
21/7/2021
11:01
Today's Singer headlines to its research note: EKF recently unveiled a strategy for driving growth in the business over the next few years. It will be led by a refreshed executive management team and board, building on renewed strength in the core business and opportunities in developing wider contract development and manufacturing activities. Accretive bolt-on acquisitions will also be considered, all funded by the current strong net cash position of the group. Overall, the ambition is to deliver sustainable double-digit EBITDA growth into the medium term. This note takes a detailed look at the growth drivers and opportunities now in prospect. In addition to introducing conservative formal FY22 & FY23 estimates for the first time, we also look at a range of potential scenarios, one of which shows how EBITDA could reach £45.9m by FY24. Putting that on a multiple of 13- 15x implies a potential Enterprise Value of £597-688m, against a current EV of £314m. Successful delivery should therefore lead to material value creation. Does anyone have full access to this report?
welshborderer
21/7/2021
09:07
https://www.insidermedia.com/news/wales/first-half-revenues-soar-as-ekf-looks-ahead-with-confidence
mirandaj
21/7/2021
08:49
There is scope and indeed potential for further upgrades in my view. The managements conservative approach to forecasting and guidance to analysts is playing its part, which I am comfortable with, but the recent track record perhaps provides investors with better guidance than the current forecasts!
wan
21/7/2021
08:38
There must be scope for upgrading the forecasts for current year and year to June 22. According to my readings Sharescope 2022 showing EBITDA of £17m. They have done £12.75 in the first half of 2021. I note that the last note from Singers (may 2021) only had forecasts up to 2021 and suggested they would update forecasts for subsequent periods later this year. Anybody else got a view on the anomalies between management statements of double digit growth and current forecasts?
cgequityinvest
21/7/2021
08:18
Good update. The confidence already being shown in trading for the full year augurs well. I strongly suspect that COVID-19 sample collecting will be providing substantial revenues for some time to come, and certainly much longer than is assumed in the market forecasts out there which naturally have to be conservative in that respect. Worth noting that EKF now have around £33m of cash and liquid assets via shares with which to grow the business organically and via acquisition - around 10% of the total m/cap.
rivaldo
21/7/2021
08:00
wan, Current market forecasts certainly assume a surprising drop off in revenue, profit etc.
shanklin
21/7/2021
07:57
Another excellent trading update and confirmation that we are 'firmly' on course for the full year to be comfortably ahead of the already upgraded expectations. Given the managements conservative approach to forecasting and that the second half usually delivers a stronger performance compared to the first, it bodes well indeed for the full year outcome. And I am thus also very much looking forward to the managements delivery of the initial phases of EKF's 2021-2024 growth strategy.
wan
21/7/2021
07:09
Trading Update H1 2021 performance in-line with already upgraded management expectations Full year performance expected to be in-line with management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update for the six months ended 30 June 2021. As previously announced in our AGM statement in May, the strong trading from the beginning of the year continued into the second quarter of 2021. This continues to reflect improving trading in the core business and ongoing strong demand for our contract manufacturing services for COVID-19 sample collection devices and associated kits. The Board remains confident that trading for the full year will remain strong and will be in-line with already materially upgraded management expectations. Revenues for the six months ended 30 June 2021 were GBP38.56m (H1 2020: GBP26.33m) and the Company expects to report adjusted EBITDA(1) in the region of GBP12.75m (H1 2020: GBP8.93m). Gross cash as at 30 June 2021 was GBP20.78m and cash net of borrowings was GBP20.39m, in-line with management expectations. In addition, the Company's interest in Renalytix plc (1,002,981 shares) had a fair value of GBP10.83m, and its Verici Dx plc securities (2,677,981 shares) had a fair value of GBP1.83m, based on closing mid-market prices on 30 June 2021. Following the payment of an inaugural cash dividend of 1p per share at the end of last year (in respect of 2019) the Company has confirmed its intention to maintain a modest but progressive dividend policy, and a further dividend payment to shareholders of 1.1p per ordinary share, which it proposes to pay on 1 December 2021 to shareholders on the register at the close of business on 5 November 2021. The ex-dividend date for this timetable is 4 November 2021. The Company remains confident that its growth strategy, as outlined to shareholders at the Annual General Meeting in May, will create a business which, aside from any COVID-19 related revenues, is capable of generating significant double-digit growth in adjusted EBITDA(1) over the next 3 to 4 years. The Board believe this can be achieved by: -- investing in the existing core business to drive strong organic growth; -- maximising value from the agreement with Mount Sinai Innovation Partners; -- seeking complementary and targeted earnings-enhancing acquisitions with key strategic value to the core business; -- continuing to maximise the opportunity to assist clients to control the impact of COVID-19, and to evolve new contract manufacturing capabilities in this area to a broader range of diagnostic and other healthcare settings. EKF expects to announce its unaudited results for the six months ended 30 June 2021 in the first half of September 2021, with the date to be confirmed in a subsequent announcement.
masurenguy
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210731 19:43:00